Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

CAR T-Cell Therapy in Multiple Myeloma : Episode 1

Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient

December 5, 2024
By Omar Castaneda Puglianini, MD
Jammie Freeman, RN
  • Raja Assal

Opinion
Video

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      Now Viewing

      EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient

      EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

      EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation

      EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges

      EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment

      EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care

      EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience

      EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care

      EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy

      EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies

      Video content above is prompted by the following:

      Can you share your journey with multiple myeloma, starting with your initial diagnosis and first-line treatment?

      Recent Videos
      The Role of Molecular Testing in Ovarian Cancer Care
      The Role of Molecular Testing in Ovarian Cancer Care
      Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
      Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
      Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
      Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
      Managing Expectations: Adverse Events With Melanoma Immunotherapy
      Managing Expectations: Adverse Events With Melanoma Immunotherapy
      2 experts in this video
      NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
      2 experts in this video
      Evaluating the Impact Of UGT1A1*28 Status On Tolerability Of NALIRIFOX In mPDAC
      2 experts in this video
      NAPOLI-3 in Real World Practice: Expert Insights on Data From ASCO GI 2025
      2 experts in this video
      Managing AEs Associated With the FOLFIRINOX and NALIRIFOX Regimens in Pancreatic Cancer
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      CRS Recognition and Intervention: Timing and Clinical Features
      CRS Recognition and Intervention: Timing and Clinical Features
      Related Content
      Related Content
      From All Angles
      |
      CAR T-Cell Therapy in Multiple Myeloma
      Advertisement
      Advertisement
      Advertisement
      Advertisement
      x
      About
      Advertise
      CureToday.com
      OncLive.com
      OncNursingNews.com
      TargetedOnc.com
      Editorial
      Contact
      Terms and Conditions
      Privacy
      Do Not Sell My Personal Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.